Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Complete response in gallbladder cancer to erlotinib plus gemcitabine does not require mutation of the epidermal growth factor receptor gene: a case report.

BMC cancer - 20 Oct 2010

Mody Kabir, Strauss Edward, Lincer Robert, Frank Richard C

Abstract excerpt

BACKGROUND: Gallbladder cancer typically follows an aggressive course, with chemotherapy the standard of care for advanced disease; complete remissions are rarely encountered. The epidermal growth factor receptor (EGFR) is a promising therapeutic target but the activity of single agent oral EGFR tyrosine kinase inhibitors is low. There have been no previous reports of chemotherapy plus an EGFR-tyrosine kinase...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antimetabolites, Antineoplastic
Share to CA-19-9 Antigen

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Deoxycytidine

Share to Erlotinib Hydrochloride

Share to Gallbladder Neoplasms

Share to Gemcitabine

Share to Lymphatic Metastasis

Share to Positron-Emission Tomography

Source

Open in PubMed Open full text

Identifiers

PMID: 20961434
DOI: 10.1186/1471-2407-10-570
PMCID: PMC2972285

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Complete response in gallbladder cancer to erlotinib plus gemcitabine does not require mutation of the epidermal growth factor receptor gene: a case report.PMID 20961434Read ↗

Gallbladder cancer with EGFR mutation and its response to GemOx with erlotinib: a case report and review of literature.Semantic proximity Read ↗

A case of advanced biliary tract cancer with EGFR amplification that responded to Necitumumab and post-treatment resistance changes detected by liquid biopsySemantic proximity Read ↗

Sustained response on sequential anti-FGFR therapy in metastatic gall bladder cancer: a case report and literature review.Semantic proximity Read ↗

Sustained Response on Sequential Anti-fgfr Therapy in Metastatic Gall Bladder Cancer - a Case Report and Literature ReviewSemantic proximity Read ↗

Novel AMBRA1-ALK fusion identified by next-generation sequencing in advanced gallbladder cancer responds to crizotinib: a case reportSemantic proximity Read ↗

Response of BRCA1-mutated gallbladder cancer to olaparib: A case report.Semantic proximity Read ↗

Cetuximab, gemcitabine and capecitabine in patients with inoperable biliary tract cancer: a phase 2 study.Semantic proximity Read ↗

Cetuximab, gemcitabine, and oxaliplatin in patients with unresectable advanced or metastatic biliary tract cancer: a phase 2 study.Semantic proximity Read ↗

Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial.Semantic proximity Read ↗

Effectiveness of Olaparib Treatment in a Patient with Gallbladder Cancer with an ATM-Inactivating Mutation.Semantic proximity Read ↗

A KRAS mutation status-stratified randomized phase II trial of gemcitabine and oxaliplatin alone or in combination with cetuximab in advanced biliary tract cancer.Semantic proximity Read ↗

Somatic mutations of epidermal growth factor receptor in bile duct and gallbladder carcinoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.